COEP - שווי פירמה כולל coeptistx.com
Coeptis Therapeutics (COEP) is developing the innovative SNAP-CAR system for flexible T-cell reprogramming, enabling the adaptation of treatment for various tumors. Business success relies on clinical trial results and access to capital. This chart of current share prices reflects the enterprise value at 75.21. However, the absence of a commercial product and the early stage of NK-therapy render financial expectations high-risk.
פילוחי נתונים אנליטיים מרוכזים עבור Coeptis Therapeutics, Inc. (COEP)
Enterprise Value (EV) represents the sum of market capitalization and net debt, reflecting the total cost of acquiring a business. For Coeptis Therapeutics (COEP), this metric is critical, as the absence of revenue and rising R&D expenses make the company dependent on external financing. The price action of the company's actual acquisition value on the GURU.Markets platform allows for tracking changes in the asset's investment attractiveness. Analysis of this metric reveals the extent to which promising cell technologies are overvalued. Comparing EV with the balance sheet confirms the stability of the financial structure during early-stage trials.